Charles River director plans $10M stock sale

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Rhea-AI Filing Summary

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) is the issuer for a planned resale of its common stock under Rule 144 by director James Foster. The notice covers 33,561 shares of common stock, with an aggregate market value of $10,065,950.73, relative to 47,738,872 shares outstanding as of August 25, 2026.

The shares are to be sold through UBS Financial Services, Inc. on the NYSE, in connection with an exercise of stock options for cash on August 25, 2026. Foster also reported prior sales in the past three months totaling 103,733 shares for combined proceeds of $24,776,575.00.

Key Figures

Shares to be sold: 33,561 shares Aggregate market value of shares to be sold: $10,065,950.73 Shares outstanding: 47,738,872 shares +4 more

7 metrics

Shares to be sold 33,561 shares Common stock covered by the Rule 144 notice for August 25, 2026

Aggregate market value of shares to be sold $10,065,950.73 Market value of 33,561 CRL common shares listed in the notice

Shares outstanding 47,738,872 shares CRL common shares outstanding as of August 25, 2026

Shares sold June 29, 2026 75,000 shares Common shares sold by James Foster on June 29, 2026

Proceeds June 29, 2026 sale $16,875,000.00 Value of 75,000 CRL shares sold on June 29, 2026

Shares sold August 10, 2026 28,733 shares Common shares sold by James Foster on August 10, 2026

Proceeds August 10, 2026 sale $7,901,575.00 Value of 28,733 CRL shares sold on August 10, 2026

Key Terms

Rule 144, Form 144, attorney-in-fact, Exercise of stock options

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Form 144 regulatory

"144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

attorney-in-fact regulatory

"Signature | /s/ UBS Financial Services Inc, as attorney-in-fact for James Foster"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Exercise of stock options financial

"Common | 08/25/2026 | Exercise of stock options | Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filed for CRL disclose about planned stock sales?

The notice states that director James Foster plans to sell 33,561 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. common stock under Rule 144, with an aggregate market value of $10,065,950.73, based on market prices as of August 25, 2026.

How many CRL shares has James Foster sold in the past three months?

James Foster reported selling a total of 103,733 CRL shares in the past three months: 75,000 shares for $16,875,000.00 on June 29, 2026, and 28,733 shares for $7,901,575.00 on August 10, 2026.

What is the size of the planned CRL sale relative to shares outstanding?

The planned sale covers 33,561 shares of CRL common stock. The document lists 47,738,872 shares outstanding as of August 25, 2026, providing a reference point for the relative size of the proposed Rule 144 sale.

How will the CRL shares in this Form 144 be acquired before sale?

The shares covered by the notice are related to an exercise of stock options on August 25, 2026. The transaction is described as an option exercise for cash with the issuer as the counterparty, followed by potential resale under Rule 144.

Who is handling the planned CRL stock sale for James Foster?

The planned Rule 144 sale of 33,561 CRL shares will be handled by UBS Financial Services, Inc. at its Eleven Madison Avenue office, with the common stock listed for trading on the NYSE.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/25/2026 - 04:11 PM EDT Accepted by SEC EDGAR 08/25/2026 - 04:10 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001141722
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
SEC File Number	001-15943
Address of Issuer	251 BALLARDVALE ST WILMINGTON MASSACHUSETTS 01887
Phone	781-222-6000
Name of Person for Whose Account the Securities are To Be Sold	FOSTER JAMES C
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. Eleven Madison Avenue 4th Floor New York NY 10010	33561	10065950.73	47738872	08/25/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/25/2026	Exercise of stock options	Issuer			33561	08/25/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
James Foster 251 BALLARDVALE ST WILMINGTON MA 01887	Common	06/29/2026	75000	16875000.00
James Foster 251 BALLARDVALE ST WILMINGTON MA 01887	Common	08/10/2026	28733	7901575.00

144: Remarks and Signature

Remarks
Date of Notice	08/25/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for James Foster
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)